Skip to main content

Table 3 0–24 h wmFEV1 and trough FEV1 by GOLD subgroup (ITT population)

From: Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

Endpoint UMEC/VI 62.5/25 mcg (N = 358) FP/SAL 500/50 mcg (N = 358)
0–24 h wmFEV1 on Day 84, L, change from baseline
GOLD B a,b
 n 184 189
 mean (SD) 0.181 (0.2476) 0.096 (0.2230)
GOLD D b,c
 n 148 148
 mean (SD) 0.152 (0.2111) 0.071 (0.2038)
Trough FEV1 on Day 85, L, change from baseline
GOLD B a,b
 n 185 189
 mean (SD) 0.162 (0.2661) 0.070 (0.2340)
GOLD D b,c
 n 148 149
 mean (SD) 0.143 (0.2067) 0.049 (0.2160)
  1. Descriptive analyses of change from baseline in 0–24 h wmFEV1 on Day 84 and in trough FEV1 on Day 85 by GOLD subgroup
  2. FEV 1 forced expiratory volume in 1 s, FP/SAL fluticasone propionate/salmeterol, GOLD Global Initiative for Chronic Obstructive Lung Disease™, ITT intent-to-treat, SD standard deviation, UMEC umeclidinium, VI vilanterol, wm weighted mean
  3. aFEV1 ≥ 50 % to <80 % predicted; bAll but three patients fulfilled the exclusion criterion regarding no exacerbations in the past year—no further details of exacerbation history were collected; cFEV1 ≥ 30 % to <50 % predicted